Clinical Trial VICCPED1249
Title
An Open Label, Expanded Access Protocol using 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy in Patients with Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
Principal Investigator(s)
Details
- Protocol No. VICCPED1249
- Open Date: 08/06/2012
- Staging: NA
- Age Group: Both Child and Adult
- Scope: National
- Objective: - Provide palliative therapy with MIBG for patients with advanced neuroblastoma, pheochromocytoma, or paraganglioma - Gain more information about acute and late toxicity of 131I-MIBG therapy for patients with refractory neuroblastoma, pheochromocytoma, or paraganglioma
- Disease Sites: Pediatric Solid Tumors; Neuroblastoma (Pediatrics)
- Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
- Drugs: 131-MIBG; Iobenguane Sulfate
- Participating Institutions: Vanderbilt University
- Secondary Protocol No: Not Specified
Description
None Provided.
Eligibility
Not provided. Please call for more information.
Learn More
- Call toll-free number: 1-800-811-8480
- Use our Online self–referral form
- Print this page for your doctor
You do not have JavaScript enabled. This site works better with JavaScript turned on.
